Published in Nature on October 30, 1965
Synthesis and secretion of interferon by murine fibroblasts in response to intracellular Listeria monocytogenes. Infect Immun (1986) 4.14
Mice that lack the interferon-gamma receptor have profoundly altered responses to infection with Bacillus Calmette-Guérin and subsequent challenge with lipopolysaccharide. J Exp Med (1993) 3.48
Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care (2006) 3.19
Leukocytes and interferon in the host response to viral infections. II. Enhanced interferon response of leukocytes from immune animals. J Bacteriol (1966) 2.78
Migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity. Infect Immun (1973) 2.73
Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46
Endotoxin-induced serum factor kills malarial parasites in vitro. Infect Immun (1981) 2.30
Effect of Interferon and Interferon Inducers on Infections with a Nonviral Intracellular Microorganism, Chlamydia trachomatis. Infect Immun (1971) 2.07
Antiviral activity of polyacrylic and polymethacrylic acids. II. Mode of action in vivo. J Virol (1968) 1.78
Recombinant interleukin-1 alpha and recombinant tumor necrosis factor alpha synergize in vivo to induce early endotoxin tolerance and associated hematopoietic changes. Infect Immun (1988) 1.48
Antiviral activity of chlorite-oxidized oxyamylose, a polyacetal carboxylic acid. J Virol (1970) 1.46
Interferon induction with statolon in the intact animal. Bacteriol Rev (1967) 1.39
Hyporeactivity of infection: potential limitation to therapeutic use of interferon-inducing agents. Infect Immun (1972) 1.23
Role of cytokines (interleukin 1, tumor necrosis factor, and transforming growth factor beta) in natural and lipopolysaccharide-enhanced radioresistance. J Exp Med (1991) 1.23
Silica enhancement of murine endotoxin sensitivity. Infect Immun (1982) 1.22
Early-phase endotoxin tolerance: induction by a detoxified lipid A derivative, monophosphoryl lipid A. Infect Immun (1986) 1.18
The role of interferon in the protective effect of a synthetic double-stranded polyribonucleotide against intranasal vesicular stomatitis virus challenge in mice. J Clin Invest (1970) 1.11
Administration of endotoxin associated with lipopolysaccharide tolerance protects mice against fungal infection. Infect Immun (2000) 1.10
Effect of Corynebacterium acnes on interferon production in mice. Infect Immun (1972) 1.06
The role of individual spleen cells in the interferon response of the intact mouse. Proc Natl Acad Sci U S A (1969) 1.05
Hyporeactivity due to infection: recognition of a transferable hyporeactive factor in the serum of encephalomyocarditis virus-infected mice. Infect Immun (1974) 1.04
Effect of induced interferon in experimental rhinovirus infections in volunteers. Infect Immun (1974) 1.01
Enhancement of the lethal effects of endotoxins by interferon inducers. J Bacteriol (1969) 1.01
Potentiating Effect of Freund's Adjuvant on Interferon Production by Endotoxin or Poly rI*Poly rC. Infect Immun (1970) 0.99
Induction of murine gamma interferon production by lipopolysaccharide and interleukin-2 in Propionibacterium acnes-induced peritoneal exudate cells. Infect Immun (1987) 0.97
Expression, regulation, and function of atypical chemerin receptor CCRL2 on endothelial cells. J Immunol (2012) 0.96
Eperythrozoon coccoides. I. Effect on the interferon response in mice. Infect Immun (1971) 0.94
Mechanisms in the in vivo release of lymphokines: relationship of high and low responsiveness to other parameters of the immune response. Infect Immun (1981) 0.90
Type I and II interferons and migration inhibitory factor: production in Mycobacterium bovis BCG-infected mice desensitized with old tuberculin or lipopolysaccharide. Infect Immun (1978) 0.88
Effect of Separate and Combined Injections of Poly rI: Poly rC and Endotoxin on Reticulo-endothelial Activity, Interferon, and Antibody Production in the Mouse. Infect Immun (1971) 0.87
Influence of statolon on resistance of mice to influenza. Appl Microbiol (1969) 0.87
Resistance to Babesia spp. and Plasmodium sp. in mice pretreated with an extract of Coxiella burnetii. Infect Immun (1979) 0.87
Interferon production in mice by cell wall mutants of Salmonella typhimurium. J Virol (1967) 0.87
Mycoplasma-mediated hyporeactivity to various interferon inducers. Infect Immun (1975) 0.83
Evaluation of a topical interferon inducer in experimental influenza infection in volunteers. Antimicrob Agents Chemother (1975) 0.82
Bacterial lipopolysaccharide: oral route for interferon production in mice. Infect Immun (1972) 0.82
Hyporeactivity factor produced after induction of immune interferon in mice sensitized with BCG. Infect Immun (1978) 0.81
Combined protective effects on interferon and interferon induction on herpes simplex and ectromelia virus infections in mice. Antimicrob Agents Chemother (1981) 0.78
Hypoglycemia in mice injected with interferon inducers is not mediated by interferon. Infect Immun (1981) 0.78
Induction of interferon synthesis in mice by fractions from Nocardia. Infect Immun (1978) 0.77
Interferon production by inactivated Newcastle disease virus in cell cultures and in mice. J Bacteriol (1966) 4.15
Production and properties of migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity. J Immunol (1973) 3.88
Migration inhibitory factor and interferon in the circulation of mice with delayed hypersensitivity. Infect Immun (1973) 2.73
Influence of inhibitors of protein synthesis on interferon formation in mice. Virology (1965) 2.49
Temperature-sensitive viruses and the etiology of chronic and inapparent infections. J Infect Dis (1975) 2.38
Inhibition of protein synthesis in L cells infected with vesicular stomatitis virus. J Virol (1972) 2.29
Cells persistently infected with newcastle disease virus: I. Properties of mutants isolated from persistently infected L cells. J Virol (1969) 2.24
Characterization of a specific kinase inhibitory factor produced by vaccinia virus which inhibits the interferon-induced protein kinase. Virology (1984) 2.13
Sensitivity of ribonucleic acid and deoxyribonucleic acid viruses to different species of interferon in cell cultures. J Virol (1972) 2.09
Cells persistently infected with Newcastle disease virus. II. Ribonucleic acid and protein synthesis in cells infected with mutants isolated from persistently infected L cells. J Virol (1970) 2.04
Interferon production in mice by double-stranded synthetic polynucleotides: induction or release? Virology (1968) 1.97
Factors affecting the sensitivity of different viruses to interferon. J Virol (1970) 1.96
Comparison of interferon production in mice by bacterial endotoxin and statolon. Virology (1966) 1.88
Interferon activity associated with high molecular weight proteins in the circulation of mice injected with endotoxin or bacteria. Virology (1965) 1.85
Inhibition of induction of interferon synthesis in L-cells pretreated with interferon. Virology (1969) 1.80
Vaccinia rescue of VSV from interferon-induced resistance: reversal of translation block and inhibition of protein kinase activity. Virology (1983) 1.80
Interferon production and inhibition of host synthesis in cells infected with vesicular stomatitis virus. J Virol (1970) 1.71
Role of temperature-sensitive mutants in persistent infections initiated with vesicular stomatitis virus. J Virol (1976) 1.68
Toxic properties of a synthetic double-stranded RNA. Endotoxin-like properties of poly I. poly C, an interferon stimulator. Nature (1969) 1.61
Temperature-sensitive defect of mutants isolated from L cells persistently infected with Newcastle disease virus. J Virol (1973) 1.61
Temperature-sensitive mutants isolated from L cells persistently infected with Newcastle disease virus. J Virol (1972) 1.59
Selection of temperature-sensitive mutants during persistent infection: role in maintenance of persistent Newcastle disease virus infections of L cells. J Virol (1973) 1.57
Inhibition of murine osteogenic sarcomas by treatment with type I or type II interferon. J Natl Cancer Inst (1978) 1.49
Vaccinia specific kinase inhibitory factor prevents translational inhibition by double-stranded RNA in rabbit reticulocyte lysate. J Biol Chem (1989) 1.40
Migration inhibitory factor and type II interferon in the circulation of mice sensitized with mycobacterial components. J Immunol (1975) 1.33
Interferon production in mice by vesicular stomatitis virus. J Virol (1968) 1.26
Cellular mechanisms in the superinfection exclusion of vesicular stomatitis virus. Virology (1990) 1.24
Superinfection exclusion by vesicular stomatitis virus. Virology (1983) 1.20
Interferon-mediated inhibition of virus penetration. Proc Natl Acad Sci U S A (1983) 1.19
Temperature-sensitive mutants isolated from hamster and canine cell lines persistently infected with Newcastle disease virus. J Virol (1975) 1.17
Temperature-sensitive mutants of vesicular stomatitis virus are conditionally defective particles that interfere with and are rescued by wild-type virus. J Virol (1976) 1.17
Persistent infection with influenza A virus: evolution of virus mutants. Virology (1984) 1.15
Vaccinia-mediated rescue of encephalomyocarditis virus from the inhibitory effects of interferon. Virology (1986) 1.14
Rescue of vesicular stomatitis virus from interferon-induced resistance by superinfection with vaccinia virus. II. Effect of UV-inactivated vaccinia and metabolic inhibitors. Virology (1973) 1.14
Base mutations in the terminal noncoding regions of the genome of vesicular stomatitis virus isolated from persistent infections of L cells. Virology (1985) 1.11
Cells persistently infected with Newcastle disease virus. 3. Thermal stability of hemagglutinin and neuraminidase of a mutant isolated from persistently infected L cells. J Virol (1971) 1.10
Persistent infection of L cells with vesicular stomatitis virus: evolution of virus populations. J Virol (1978) 1.08
Abortive infection of a rabbit cornea cell line by vesicular stomatitis virus: conversion to productive infection by superinfection with vaccinia virus. J Virol (1975) 1.07
Efficacy of a cold-adapted, intranasal, equine influenza vaccine: challenge trials. Equine Vet J (2001) 1.05
Cold-adapted vaccine strains of influenza A virus act as dominant negative mutants in mixed infections with wild-type influenza A virus. Virology (1990) 1.03
Sequential disassembly of the cytoskeleton in BHK21 cells infected with vesicular stomatitis virus. Virology (1990) 1.02
Survey of interferon production and sensitivity human cell lines. Appl Microbiol (1971) 1.02
Interferon induction in mice by lipopolysaccharide from Brucella abortus. Infect Immun (1974) 1.02
Tumor suppression by a lymphokine released into the circulation of mice with delayed hypersensitivity. J Natl Cancer Inst (1975) 1.01
Influence of inhibitors of protein synthesis on interferon formation in mice. II. Comparison of effects of glutarimide antibiotics and tenuazonic acid. Virology (1970) 0.99
Viral interference-dominance of mutant viruses over wild-type virus in mixed infections. Microbiol Rev (1987) 0.99
Properties of interferon induced by specific antigens. Tex Rep Biol Med (1977) 0.98
Response of interferon-treated cells to diphtheria toxin. Infect Immun (1971) 0.97
Generation and amplification of temperature-sensitive mutants during serial undiluted passages of vesicular stomatitis virus. Virology (1981) 0.97
Human lymphoblastoid cell lines of B- and T-cell origin: different responses to infection with vesicular stomatitis virus. Virology (1981) 0.96
Cellular source of interferons in the circulation of mice with delayed hypersensitivity. Infect Immun (1977) 0.96
Relation of interferon synthesis to abortive replication of Newcastle disease virus in L cells. J Virol (1968) 0.95
Rescue of vesicular stomatitis virus from interferon-induced resistance by superinfection with vaccinia virus. I. Rescue in cell cultures from different species. Virology (1973) 0.94
Antiviral activity of an ether-extracted nonviable preparation of Brucella abortus. Infect Immun (1974) 0.94
Varied responses of human B-lymphoblastoid cell lines to infection with vesicular stomatitis virus. Virology (1982) 0.93
Safety, efficacy, and immunogenicity of a modified-live equine influenza virus vaccine in ponies after induction of exercise-induced immunosuppression. J Am Vet Med Assoc (2001) 0.93
Dominance of temperature-sensitive phenotypes. I. Studies of the mechanism of inhibition of the growth of wild-type vesicular stomatitis virus. Virology (1986) 0.93
Dominant-negative mutants as antiviral agents: simultaneous infection with the cold-adapted live-virus vaccine for influenza A protects ferrets from disease produced by wild-type influenza A. J Infect Dis (1991) 0.93
BrucELISA: an enzyme-antibody immunoassay for detection of Brucella abortus antibodies in milk: correlation with the Brucella ring test and with shedding of viable organisms. J Clin Microbiol (1981) 0.93
Inhibition of pseudorabies virus replication by vesicular stomatitis virus. II Activity of defective interfering particles. J Virol (1976) 0.93
Prolonged application of interferon and "aging" of human diploid fibroblasts. Proc Soc Exp Biol Med (1971) 0.92
Involvement of a chemical moiety of bacterial lipopolysaccharide in production of interferon in animals. J Infect Dis (1973) 0.92
Effect of pH on the protective action of interferon in L cells. J Virol (1968) 0.92
Dominance of temperature-sensitive phenotypes. II. Vesicular stomatitis virus mutants from a persistent infection interfere with shut-off of host protein synthesis by wild-type virus. Virology (1987) 0.91
The genes associated with trans-dominance of the influenza A cold-adapted live virus vaccine. Virology (1991) 0.91
Rapid inhibition of pinocytosis in baby hamster kidney (BHK-21) cells following infection with vesicular stomatitis virus. J Cell Biol (1983) 0.89
Type I and II interferons and migration inhibitory factor: production in Mycobacterium bovis BCG-infected mice desensitized with old tuberculin or lipopolysaccharide. Infect Immun (1978) 0.88
Interferon treatment inhibits pinocytosis. Mol Cell Biol (1983) 0.87
In vitro susceptibility of selected isolates of Brucella abortus to penicillin. Am J Vet Res (1982) 0.87
Interferon production in mice by cell wall mutants of Salmonella typhimurium. J Virol (1967) 0.87
Augmentation of natural killer cell activity in mice by Bru-Pel. J Immunother (1991) (1991) 0.87
Hydrocephalus in weanling mice induced by a temperature-sensitive mutant of vesicular stomatitis virus. J Neuropathol Exp Neurol (1982) 0.87
A new modified live equine influenza virus vaccine: phenotypic stability, restricted spread and efficacy against heterologous virus challenge. Equine Vet J (2001) 0.86
Effect of exogenous interferon on L cells persistently infected with Newcastle disease virus. Infect Immun (1972) 0.86
Novel phenotype of RNA synthesis expressed by vesicular stomatitis virus isolated from persistent infection. J Virol (1982) 0.85
Antiviral activity of Brucella abortus preparations; separation of active components. Infect Immun (1976) 0.85
Alteration of vesicular stomatitis virus L and NS proteins by uv irradiation: implications for the mechanism of host cell shut-off. Virology (1988) 0.84
Dominance of cold-adapted influenza A virus over wild-type viruses is at the level of RNA synthesis. Virology (1994) 0.84
Interferon inhibits the growth of Legionella micdadei in mouse L cells. J Interferon Res (1986) 0.83
Interferon production in mice by cell wall mutants of Salmonella typhimurium. II. Effect of purified glycolipids from S and Re chemotypes. Biochem Biophys Res Commun (1968) 0.83
Inhibition of pseudorabies virus replication by vesicular stomicles virus I. Activity of infectious and inactivated B particles. J Virol (1976) 0.83
The L protein of a VSV mutant isolated from a persistent infection is responsible for viral interference and dominance over the wild-type. Virology (1989) 0.83
Bacterial lipopolysaccharide: oral route for interferon production in mice. Infect Immun (1972) 0.82
Further studies of the RNA synthesis phenotype selected during persistent infection with vesicular stomatitis virus. Virology (1984) 0.82
Viral ribonuclei acid synthesis by Newcastle disease virus mutants isolated from persistently infected L cells: effect of interferon. J Virol (1972) 0.82
Proposal for a uniform nomenclature for defective interfering viruses of vesicular stomatitis virus. J Virol (1980) 0.82
Urea and thermal mutants of poliovirus. J Bacteriol (1966) 0.81
Antitumor activity of interferon against murine osteogenic sarcoma in vitro and in vivo. Cancer Treat Rep (1978) 0.81
Persistence of vesicular stomatitis virus in interferon-treated cell cultures. Virology (1975) 0.80
Molecular species of circulating interferon in mice injected with Newcastle disease virus. Virology (1968) 0.79
Interferon production in mice by components of Salmonella minnesota R595 lipid A. Infect Immun (1976) 0.79
Examination of "species specificity" of avian interferons. Nature (1970) 0.78
Antitumor activity of a Brucella abortus preparation. Infect Immun (1977) 0.77
Induction of interferon by temperature-sensitive mutants of Newcastle disease virus. Virology (1978) 0.77
Restriction of vesicular stomatitis virus in a nonpermissive rabbit cell line is at the level of protein synthesis. Virology (1982) 0.77
Escherichia coli endotoxin effect on a methylcholanthrene-induced sarcoma in the hamster cheekpouch. Proc Soc Exp Biol Med (1977) 0.77